Companies
UC
STOXX 600Health Care· Belgium
UCB
ChallengerUCB
$263.90
+2.01%
Open $255.00·Prev $258.70
as of 17 Apr
CHALLENGER
Power Core
UCB's moat is dual IL-17 inhibition via BIMZELX, a bispecific antibody that simultaneously neutralizes both IL-17A and IL-17F, creating a differentiated efficacy profile that competitors cannot replicate without developing their own bispecific molecules from scratch.
Published18 Apr 2026
UniverseSTOXX 600
SectorHealth Care
↑
Direction of Movement
upward
ROC 200
+62.2%
UCB
UCB
$263.90
+2.01%
Open $255.00·Prev $258.70
as of 17 Apr
↑Undervalued by 50%
DCF Fair Value: $532.71
News
No recent news available.
mOS zones are proprietary L17X overlays and do not constitute trading signals or investment advice.